Skip to main content

Multiple Myeloma Specialty Channel

Multiple Myeloma
Specialty Channel
FDA Approval
01/27/2026
Gina Tomaine
On January 27, 2026, the FDA granted approval to daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma who are ineligible for autologous...
On January 27, 2026, the FDA granted approval to daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma who are ineligible for autologous...
On January 27, 2026, the FDA...
01/27/2026
Oncology
News
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
News
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
Conference Coverage
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology
Joshua Richter, MD
Conference Coverage
12/01/2025
Joshua Richter, MD
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares...
12/01/2025
Oncology
Mark Bustoros, MD
Conference Coverage
12/01/2025
Mark Bustoros, MD
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how...
12/01/2025
Oncology
FDA Approval
11/06/2025
Gina Tomaine
On November 6, 2025, the FDA granted approval to daratumumab and hyaluronidase-fihj for the treatment of patients with high-risk smoldering multiple myeloma.
On November 6, 2025, the FDA granted approval to daratumumab and hyaluronidase-fihj for the treatment of patients with high-risk smoldering multiple myeloma.
On November 6, 2025, the FDA...
11/06/2025
Oncology

News

News
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
News
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
Conference Coverage
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology
Joshua Richter, MD
Conference Coverage
12/01/2025
Joshua Richter, MD
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares...
12/01/2025
Oncology
Mark Bustoros, MD
Conference Coverage
12/01/2025
Mark Bustoros, MD
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how...
12/01/2025
Oncology
News
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology

Interactive Features

Quiz
10/30/2025
Emily Estrada
True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.
True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.
True or False: According to...
10/30/2025
Oncology
Quiz
10/24/2025
True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...
True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...
True or False: For patients with...
10/24/2025
Oncology
Quiz
09/19/2025
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with...
09/19/2025
Oncology
Quiz
08/04/2025
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical...
08/04/2025
Oncology
Quiz
07/17/2025
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients...
07/17/2025
Oncology
Quiz
06/16/2025
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥...
06/16/2025
Oncology
Quiz
05/01/2025
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?
According to a systematic review...
05/01/2025
Oncology
Quiz
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology
Quiz
01/30/2024
According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...
According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...
According to an interim analysis...
01/30/2024
Oncology